FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* ULLIAN ELAINE (First) (Middle)					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									tionship of Reporting all applicable) Director Officer (give title below)		g Person(s) to Issu 10% Own Other (sp below)		wner
C/O VEI	`	RMACEUTICA	,			Date of /01/20		est Trar	saction	(Mon	th/Day/Year)								
50 NOR	ΓHERN AV	ENUE			4.1	f Amer	ndmer	nt, Date	of Origi	inal Fi	led (Month/D	ay/Year)		. Indiv	ridual or .	Joint/Group	Filing	g (Check Ap	plicable
(Street) BOSTON MA 02210				_									X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																
		Tab	le I - N	lon-Deri	vative	Sec	uriti	ies Ad	quire	d, D	isposed o	of, or B	enefici	ally	Owned	l			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Yea		Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar					es ially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s)			(Instr. 4)		
Common	mon Stock		07/01/2	2014				M		5,000	A	\$34.	32	2 10,265			D		
Common	Stock			07/01/2	2014				S ⁽¹⁾		200	D	\$94.09	(2)(3)	10,065			D	
Common	Stock			07/01/2	2014				S ⁽¹⁾		4,800	D	\$95.26	(3)(4)	5,265 D				
		T	able II								posed of converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	4. Transa Code (8)			ivative urities uired or oosed O) tr. 3, 4	6. Date Exerc Expiration Do (Month/Day/)		ate	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s B Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amour or Numbe of Shares	er					
Stock Option (right to	\$34.32	07/01/2014			M			5,000	(5))	05/31/2016	Common Stock	5,000		\$0.00	10,000		D	

Explanation of Responses:

- 1. Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$94.09 (range \$93.79 to \$94.39).
- 3. Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$95.26 (range \$94.80 to \$95.65).
- 5. Fully vested.

Remarks:

Kenneth L. Horton, Attorney-

07/03/2014

In-Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.